{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:10:52Z","timestamp":1791040252675,"version":"4.1.0"},"reference-count":84,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:00:00Z","timestamp":1334620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background:<\/jats:italic> T\u2010cell lymphomas make up approximately 10\u201315% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia. <jats:italic>Diagnosis:<\/jats:italic> The diagnosis of aggressive peripheral T\u2010cell lymphoma (PTCL) is usually made using the WHO classification. The ability of hematopathologists to reproducibly diagnose aggressive PTCL is lower than for aggressive B\u2010cell lymphomas, with a range of 72\u201397% for the aggressive PTCLs. <jats:italic>Risk Stratification<\/jats:italic>: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography (PET) scans appear to be useful as they are in aggressive B\u2010cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large\u2010cell lymphoma\u2014particularly young patients with the anaplastic lymphoma kinase positive subtype. <jats:italic>Risk Adapted Therapy:<\/jats:italic> Anaplastic large\u2010cell lymphoma is the only subgroup to have a good response to a cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)\u2010like regimen. Angioimmunoblastic T\u2010cell lymphoma has a prolonged disease\u2010free survival in only \u223c20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL\u2010not otherwise specified (NOS) is not one disease. Anthracycline containing regimens have disappointing results and a new approach is needed. NK\/T\u2010cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy containing regimens. Enteropathy associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 87:511\u2013519, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23144","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T11:12:09Z","timestamp":1334661129000},"page":"511-519","source":"Crossref","is-referenced-by-count":64,"title":["The aggressive peripheral T\u2010cell lymphomas: 2012 update on diagnosis, risk stratification, and management"],"prefix":"10.1002","volume":"87","author":[{"given":"James O.","family":"Armitage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008265532487"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197410)34:8 <1488::AID-CNCR2820340822>3.0.CO;2-C"},{"issue":"2","key":"e_1_2_6_6_2","first-page":"29","article-title":"Cytological and functional criteria for the classification of malignant lymphomata","volume":"31","author":"Lennert K","year":"1975","journal-title":"Br J Cancer"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_6_8_2","volume-title":"World Health Organization Classification of Tumors","author":"Jaffe E","year":"2001"},{"key":"e_1_2_6_9_2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.320"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65454-5"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64441-0"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200103000-00002"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-227579"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-055145"},{"key":"e_1_2_6_17_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0494-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm265"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701344915"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08335.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq415"},{"issue":"4","key":"e_1_2_6_23_2","article-title":"FDG\u2010PET in the staging and prognosis of T\u2010cell lymphoma [Abstract]","volume":"22","author":"Casulo C","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90553-4"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105759"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4197"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp418"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)90004-1"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)91754-3"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00302-4"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335216"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65736-7"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.036"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.11.4265.bloodjournal88114265"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.021"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcpc0800380"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21062"},{"key":"e_1_2_6_41_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology for Non\u2010Hodgkins Lymphomas. (TCEL\u20101) 2011;Version 1.2012:www.NCCN.org."},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3727"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1764"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.5999"},{"key":"e_1_2_6_46_2","first-page":"117","article-title":"Brentuximab Vedotin (SGN\u201035) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A phase 2 study update [Abstract]","author":"Advani R","year":"2011","journal-title":"Blood"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1013224"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr140"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.585"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-364"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08003.x"},{"key":"e_1_2_6_52_2","first-page":"106","article-title":"Rituximab in combination with CHOP regimen in angioimmunoblastic T\u2010cell lymphomas (AITL): Preliminary results in 9 patients treated in a single institution [Abstract]","author":"Joly B","year":"2005","journal-title":"Blood"},{"key":"e_1_2_6_53_2","first-page":"28","article-title":"Rituximab in combination with CHOP regimen in angioimmunoblastic T\u2010cell lymphoma: Results of the phase II RAIL trial\u2014A prospective study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [Abstract]","author":"Joly B","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601137658"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403936"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm579"},{"issue":"4","key":"e_1_2_6_57_2","article-title":"Response to lenalidomide in heavily pre\u2010treated angioimmunoblastic T\u2010cell\u2010lymphoma (AITL) [Abstract]","volume":"22","author":"Rentschler J","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"e_1_2_6_58_2","article-title":"Long term disease control and overall survival after early dose intensification in T\u2010NHL depend on specific entities [Abstract]","volume":"22","author":"Marks R","year":"2011","journal-title":"Ann Oncol"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.12.6219"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4628"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"issue":"15","key":"e_1_2_6_62_2","article-title":"Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial [Abstract]","volume":"28","author":"Foss FM","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"e_1_2_6_63_2","article-title":"The efficacy of bortezomib CHOP in patients with advanced stage T or NK\/T cell lymphomas: The results of multicenter phase II study [Abstract]","volume":"116","author":"Kim SJ","year":"2010","journal-title":"Blood"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"e_1_2_6_65_2","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_66_2","first-page":"116","article-title":"Gemcitabine, ifosfamide, oxaliplatin (GIFOX) as first\u2010line treatment in high\u2010risk peripheral T\u2010cell\/NK lymphomas: A phase II trial [Abstract]","author":"Corazzelli G","year":"2010","journal-title":"Blood"},{"issue":"2","key":"e_1_2_6_67_2","article-title":"Dose\u2010dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T\u2010cell lymphomas (PTCLs)\u2014Overall and subtype\u2010specific results of a phase II study from Nordic lymphoma group [Abstract]","volume":"94","author":"d'Amore F","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_6_68_2","first-page":"116","article-title":"Favorable outcome in ALK\u2010negative anaplastic large\u2010cell lymphoma following intensive inducation chemotherapy and autologous stem cell transplantation (ASCT): A prospective study by the Nordic Lymphoma Group (NLG\u2010T\u201001)[Abstract]","author":"Relander T","year":"2010","journal-title":"Blood"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25377"},{"key":"e_1_2_6_72_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood.V116.21.288.288","article-title":"Phase I\/II study of dasatinib in relapsed or refractory non\u2010Hodgin's lymphoma (NHL) [Abstract]","volume":"116","author":"William BM","year":"2010","journal-title":"Blood"},{"key":"e_1_2_6_73_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.V118.21.95.95","article-title":"Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of auror A kinase (AAK), in patients (pts) with aggressive B\u2010 an T\u2010Cell non\u2010Hodgkin lymphoma (NHL) [Abstract]","volume":"118","author":"Friedberg J","year":"2011","journal-title":"Blood"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2573"},{"key":"e_1_2_6_75_2","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3\u2212 CD56+ non\u2010Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Drenou B","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053547"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982090"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.4.795"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-231324"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1675"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn119"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109099342"},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705615"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn751"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23144","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:37:01Z","timestamp":1700573821000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,17]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/ajh.23144"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23144","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,17]]}}}